Hexaspray oromucosal spray 750 mg/30 g in a 30 g bottle

Pharmacological properties

Hexaspray is a product with antiseptic, analgesic and anti-inflammatory properties.

The pharmaceutically active ingredient of Hexaspray is biclotimol – a derivative of thymol with antibacterial activity against Staphylococcus spp., Streptococcus spp., Micrococci and corynebacteria. Causes coagulation of bacterial wall proteins. Also has a local anti-inflammatory effect along with an analgesic effect.

Extremely slow absorption of biclotimol, due to its connection with mucous membrane proteins, provides a long-lasting effect of the drug in the oral cavity.

Indications

Topical symptomatic therapy of diseases of the oral cavity and nasopharynx of an infectious and inflammatory nature:

• aphthous stomatitis;
• periodontitis;
• gingivitis;
• pharyngitis;
• angina.

Application

Locally for adults and children aged 2.5 years – 2 injections 3 times a day. course ≤5 days.

Shake the bottle before use, hold vertically when irrigating the oral cavity.

Contraindications

• Hypersensitivity to the drug; children under 2.5 years of age (risk of laryngospasm).

Side effects

Skin disorders. very rarely, lip edema, skin rashes, urticaria, erythema, Quincke’s edema may develop.

The presence of ingredients such as soy lecithin and methyl parahydroxybenzoate in the drug causes the likelihood of allergic reactions in certain categories of patients.

Special instructions

If the period of use of Hexaliz is increased to 5 days, dysbiotic disorders in the oral cavity and the likelihood of the spread of bacterial or fungal infection may develop.

Given the likelihood of such undesirable interactions as inactivation or antagonism, it is necessary to refrain from simultaneous use with other topical antiseptic agents.

If the patient’s condition worsens, for example, fever develops, or in the absence of positive dynamics within 5 days, a re-examination of the patient is required with subsequent revision of the therapeutic strategy.

There is no information on the safety of the drug during pregnancy and breastfeeding due to the lack of adequate and well-controlled studies involving these categories of patients.

No effect on the reaction rate when driving or using other mechanisms has been observed.

Interactions

Unknown.

Overdose

There are no data on cases of overdose.

Storage conditions

At a temperature of ≤25 °C in a place protected from light and inaccessible to children.